{"id":1127,"date":"2024-01-17T08:55:52","date_gmt":"2024-01-17T08:55:52","guid":{"rendered":"https:\/\/www.the-nash-education-program.com\/?page_id=1127"},"modified":"2024-01-17T08:55:52","modified_gmt":"2024-01-17T08:55:52","slug":"who-is-at-risk-for-nash","status":"publish","type":"page","link":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/","title":{"rendered":"WHO IS AT RISK FOR NASH?"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">PEOPLE WITH OBESITY<\/h2>\n\n\n\n<p>Both NASH and NAFLD are highly prevalent in populations suffering from obesity, but exact figures remain difficult to estimate. A study analyzing 12 observational and transversal studies, involving a total of 1,620 patients with severe obesity (BMI&gt;40), showed that 91% had NAFLD (range:85-98%) and 37% had NASH (range: 24-98%).<sup>1<\/sup><\/p>\n\n\n\n<p>In another study quoted in American Association for the Study of Liver Diseases (AASLD) Practice Guidelines 2018, 80.2% of individuals with BMI &gt; 35mg\/m<sup>2<\/sup>&nbsp;had obesity-related liver disease (steatosis, or NASH and\/or fibrosis).<sup>2-3<\/sup><\/p>\n\n\n\n<p><strong>NAFLD: 70% or more<sup>4<\/sup><\/strong><br><strong>NASH: 25-30%<sup>5<\/sup><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">LOOKING FORWARD<\/h2>\n\n\n\n<p>Obesity has reached epidemic proportions over the last 30 years. And its prevalence continues to increase. According to the Organization for Economic Cooperation and Development (OECD), 47% of adults in the United States will suffer from obesity by 2030, compared to 37.7% in 2014. This represents a 25% increase in obesity by 2030.<sup>6<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/diabetes.png\" alt=\"\"\/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">PEOPLE WITH TYPE 2 DIABETES<\/h2>\n\n\n\n<p>More than 500 million people are affected by type 2 diabetes worldwide.<sup>7<\/sup>&nbsp;According to several studies and AASLD Practice Guidelines, around one third to two thirds of diabetic patients have NAFLD.<sup>2<\/sup><\/p>\n\n\n\n<p><strong>NAFLD: 70% or more<sup>2,8<\/sup><\/strong><br><strong>NASH: 25-30%<sup>5<\/sup><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">LOOKING FORWARD<\/h2>\n\n\n\n<p>Worldwide diabetes rates are expected to grow by about 55% by the year 2035, according to the International Diabetes Federation, which means that the population at risk of NAFLD\/NASH will increase dramatically over the next few decades.<sup>2,9<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">ESTABLISHED RISK FACTORS INCLUDE<sup>2<\/sup><\/h2>\n\n\n\n<ul>\n<li>Genetic variation linked to patatin-like phospholipase domain-containing protein 3 (PNPLA3)<\/li>\n\n\n\n<li>Obesity<\/li>\n\n\n\n<li>Type 2 diabetes<\/li>\n\n\n\n<li>Dyslipidemia<\/li>\n\n\n\n<li>Hypertension<\/li>\n\n\n\n<li>Insulin resistance<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels<\/li>\n\n\n\n<li>Metabolic syndrome (any three of the five features):\n<ul>\n<li>Impaired fasting glucose<\/li>\n\n\n\n<li>Raised triglyceride level<\/li>\n\n\n\n<li>Low high-density lipoprotein (HDL)<\/li>\n\n\n\n<li>Increased waist circumference<\/li>\n\n\n\n<li>High blood pressure<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">CONDITIONS ASSOCIATED WITH NAFLD<sup>2<\/sup><\/h2>\n\n\n\n<ul>\n<li>Obstructive sleep apnea<\/li>\n\n\n\n<li>Colorectal cancer<\/li>\n\n\n\n<li>Osteoporosis<\/li>\n\n\n\n<li>Psoriasis<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Endocrinopathies<\/li>\n\n\n\n<li>Hypothyroidism<\/li>\n\n\n\n<li>Polycystic ovary syndrome independent of obesity<\/li>\n<\/ul>\n\n\n\n<p><a href=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/what-is-nash\/how-is-nash-diagnosed\/\">HOW IS NASH DIAGNOSED?<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.waybackmachinedownloader.com\/\">EXPLORE OUR EDUCATIONAL BROCHURES<\/a><\/p>\n\n\n\n<p>References<\/p>\n\n\n\n<ol>\n<li>Machado M, Marques-Vidal P, Cortex-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery.&nbsp;<em>J Hepatol<\/em>. 2006;45(4):600-606.<\/li>\n\n\n\n<li>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.&nbsp;<em>Hepatology<\/em>. 2018;67(1):328-357.<\/li>\n\n\n\n<li>Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery.&nbsp;<em>Surg Obes Relat Dis<\/em>. 2015;11(1):137-41.<\/li>\n\n\n\n<li>Dhir G,Cusi K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.&nbsp;<em>J Investig Med<\/em>. 2018;66(1):7-10.<\/li>\n\n\n\n<li>Anstee QM1, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.&nbsp;<em>Nat Rev Gastroenterol Hepatol<\/em>. 2013;10(6):330-44.<\/li>\n\n\n\n<li>Organisation for Economic Co-operation and Development (OECD). Obesity Update 2017. https:\/\/www.oecd.org\/els\/health-systems\/Obesity-Update-2017.pdf. Published 2017. Accessed October 8, 2019.<\/li>\n\n\n\n<li>Kaiser AB, Zhang N, Van Der Pluijm W. Global prevalence of Type 2 diabetes over the next ten years.&nbsp;<em>Diabetes<\/em>. 2018;67(Suppl 1). https:\/\/diabetes.diabetesjournals.org\/content\/67\/Supplement_1\/202-LB. Accessed October 10, 2019.<\/li>\n\n\n\n<li>Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.&nbsp;<em>Diabetes Care<\/em>. 2017;40(3):419-430.<\/li>\n\n\n\n<li>Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035.\u00a0<em>Diabetes Res Clin Pract<\/em>. 2014;103:137-149.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>PEOPLE WITH OBESITY Both NASH and NAFLD are highly prevalent in populations suffering from obesity, but exact figures remain difficult &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"WHO IS AT RISK FOR NASH?\" class=\"read-more button\" href=\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/#more-1127\" aria-label=\"More on WHO IS AT RISK FOR NASH?\">Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":16,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ub_ctt_via":"","footnotes":""},"featured_image_src":null,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>WHO IS AT RISK FOR NASH? - NASH Disease<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WHO IS AT RISK FOR NASH? - NASH Disease\" \/>\n<meta property=\"og:description\" content=\"PEOPLE WITH OBESITY Both NASH and NAFLD are highly prevalent in populations suffering from obesity, but exact figures remain difficult ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/\" \/>\n<meta property=\"og:site_name\" content=\"NASH Disease\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/diabetes.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/\",\"url\":\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/\",\"name\":\"WHO IS AT RISK FOR NASH? - NASH Disease\",\"isPartOf\":{\"@id\":\"https:\/\/www.the-nash-education-program.com\/#website\"},\"datePublished\":\"2024-01-17T08:55:52+00:00\",\"dateModified\":\"2024-01-17T08:55:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.the-nash-education-program.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What is NASH?\",\"item\":\"https:\/\/www.the-nash-education-program.com\/what-is-nash\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"WHO IS AT RISK FOR NASH?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/#website\",\"url\":\"https:\/\/www.the-nash-education-program.com\/\",\"name\":\"NASH Disease\",\"description\":\"The NASH Education Program\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.the-nash-education-program.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WHO IS AT RISK FOR NASH? - NASH Disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/","og_locale":"en_US","og_type":"article","og_title":"WHO IS AT RISK FOR NASH? - NASH Disease","og_description":"PEOPLE WITH OBESITY Both NASH and NAFLD are highly prevalent in populations suffering from obesity, but exact figures remain difficult ... Read more","og_url":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/","og_site_name":"NASH Disease","og_image":[{"url":"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/diabetes.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/","url":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/","name":"WHO IS AT RISK FOR NASH? - NASH Disease","isPartOf":{"@id":"https:\/\/www.the-nash-education-program.com\/#website"},"datePublished":"2024-01-17T08:55:52+00:00","dateModified":"2024-01-17T08:55:52+00:00","breadcrumb":{"@id":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/who-is-at-risk-for-nash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.the-nash-education-program.com\/"},{"@type":"ListItem","position":2,"name":"What is NASH?","item":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/"},{"@type":"ListItem","position":3,"name":"WHO IS AT RISK FOR NASH?"}]},{"@type":"WebSite","@id":"https:\/\/www.the-nash-education-program.com\/#website","url":"https:\/\/www.the-nash-education-program.com\/","name":"NASH Disease","description":"The NASH Education Program","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.the-nash-education-program.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/1127"}],"collection":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/comments?post=1127"}],"version-history":[{"count":0,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/1127\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/16"}],"wp:attachment":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/media?parent=1127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}